Life sciences real estate is showing two opposing signals: elevated vacancy and slowing leasing on one side, and major capital commitments and fund formation on the other. This episode explains why both are true and what the divergence means for 2026.

We break down the sector’s repricing, the impact of new institutional capital, Big Pharma investment, and the widening gap between core and secondary markets.

A concise, data-driven look at a sector in reset — not decline.

CRE360 Signal™.